{"classes":[{"categories":[{"measurements":[{"comment":"Median was not reached.","groupId":"OG000","lowerLimit":"1.5","upperLimit":"19.9","value":"NA"},{"comment":"Median was not reached.","groupId":"OG001","lowerLimit":"1.7","upperLimit":"15.2","value":"NA"},{"comment":"Median was not reached.","groupId":"OG002","lowerLimit":"0.5","upperLimit":"22.3","value":"NA"},{"groupId":"OG003","lowerLimit":"1.0","upperLimit":"3.7","value":"3.4"},{"comment":"Median was not reached.","groupId":"OG004","lowerLimit":"1.08","upperLimit":"17.25","value":"NA"},{"comment":"Median was not reached.","groupId":"OG005","lowerLimit":"0.39","upperLimit":"19.81","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"}],"units":"Participants"}],"description":"The OS was defined as the time from the date of first dose to the date of death due to any cause.","dispersionType":"Full Range","groups":[{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG000","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 0.400 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q3W on Day 1 of each 21-day treatment cycle until treatment discontinuation.","id":"OG001","title":"Part 2 (Dose Expansion): Schedule C: Modakafusp Alfa + Dexamethasone"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG002","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa"},{"description":"Participants received modakafusp alfa 1.500 mg/kg infusion, IV, and dexamethasone 40 mg, orally, Q4W on Day 1 of each 28-day treatment cycle until treatment discontinuation.","id":"OG003","title":"Part 2 (Dose Expansion): Schedule D: Modakafusp Alfa + Dexamethasone"},{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG004","title":"Part 3 (Dose Extension): Modakafusp Alfa 120 mg"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG005","title":"Part 3 (Dose Extension): Modakafusp Alfa 240 mg"}],"paramType":"MEDIAN","populationDescription":"The SAS included all enrolled participants who received at least 1 dose, even if incomplete, of TAK-573. The FAS included all participants who received at least 1 dose, even an incomplete dose, of modakafusp alfa, in the Part 3 extension cohorts. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Up to 34.7 months in Part 2; Up to 20.5 months in Part 3","title":"Parts 2 and 3: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}